Highlights

• Lycopodium Limited shares surged 13.50% to $21.36 by 15:17 AEST on Wednesday 19 August 2026, one of the strongest performances on the Australian market.

• There is no ambiguity here.

• According to the FY26 result, Revenue rose 11% to $377.5 million from $340.3 million in FY25.

• The immediate items are webinar commentary and any broker revisions that follow.

Lycopodium Limited shares surged 13.50% to $21.36 by 15:17 AEST on Wednesday 19 August 2026, one of the strongest performances on the Australian market. The move implies a previous close of roughly $18.82. The Volume tells the real story. Some 550,200 shares changed hands against a relative-volume reading of 10.99 - turnover running at almost eleven times the stock's normal pace. Readings above 2.

What is driving the move

There is no ambiguity here. Lycopodium released its full-year results for the 12 months to 30 June 2026 on the morning of 19 August, exactly as flagged to the ASX on 27 July, when it notified the market that FY2026 results would be published that day alongside an investor webinar at 11:00am AEST hosted by the Managing Director and Chief Financial Officer. What matters is *which* part of the release moved the stock. The FY26 numbers were, on their face, a mixed result - profit went backwards.

Recent developments and operating picture

According to the FY26 result, revenue rose 11% to $377.5 million from $340.3 million in FY25. But EBITDA fell 13% to $59.5 million from $68.5 million, and net profit after tax declined 5% to $40.2 million from $42.3 million. Reuters separately reported the attributable NPAT figure of A$40.2 million. Earnings Per Share eased to 101.1 cents from 106.4 cents. The compression is visible in the margin: the company noted margins eased as revenue expanded, with the NPAT Margin falling to 10.6%. In plain terms, Lycopodium bought growth - more revenue, more staff, more geographic reach - at the cost of near-term profitability. Against that, three things stood out. First, the dividend.

Business, numbers and context

Lycopodium is an engineering and project delivery consultancy. It designs, engineers and manages the construction of process plants - predominantly for Mining clients, historically gold, but increasingly across base metals and critical minerals. Critically, it is an asset-light services business, not a construction contractor carrying fixed-price completion risk on its own balance sheet. It sells engineering hours and project management expertise, largely on EPCM terms - which is why it can run over $100 million of net cash and pay out most of its earnings.

Opportunity and risks

The case is straightforward: FY26 was the Investment year and FY27 is the harvest. A $661 million committed contract book and guidance for 50% revenue growth suggest the work has already been won, not merely hoped for. The 69% Dividend increase is management signalling confidence with cash rather than words. And $106.2 million of cash against a services cost base means the company can fund expansion, absorb a delay, or return Capital without approaching shareholders - while its Toronto and Cape Town hubs give it...

What comes next

The immediate items are webinar commentary and any broker revisions that follow. Beyond that, the tests are contract announcements through the first half of FY27 that validate the $540-580 million revenue path, the February 2027 half-year result showing whether margins have stabilised, and the record and payment dates for the 37-cent final dividend.

Bottom line

Lycopodium's FY26 was not a good profit year - EBITDA fell 13% and NPAT slipped 5% as margins gave ground to growth. The 13.5% rally on almost eleven times normal volume was not a verdict on that year; it was a verdict on FY27 guidance...